Skip to content
Roboearth – Lifestyle
Author:
Cellectis Inc.
Cellectis Receives FDA RMAT Designation for lasme-cel, the First Allogeneic CAR-T Therapy in a Pivotal Trial for Patients with r/r B-ALL
June 9, 2026
Cellectis’ Annual Shareholders General Meeting to be Held on June 25, 2026
May 20, 2026
←
Previous Page
1
2